팝업레이어 알림

팝업레이어 알림이 없습니다.

뇌질환의 혁신, 뉴로벤티(NeuroVenti)

INNOVATING TREATMENT
FOR BRAIN DEVELOPMENTAL DISORDERS

Development of patient-customized novel
drugs for optimal brain function utilization

DISCOVERING CANDIDATES FOR
OPTIMIZED BRAIN DISEASE TREATMENT

Provision of customized solutions
for intractable brain diseases

INTEGRATING PLATFORMS
OF TREATMENT
FOR BRAIN DISEASES

Holistic approach to brain well-being
from cradle to grave

NeuroVenti

NeuroVenti is a global biotech startup
leading the development of neuroprotective
and therapeutic agents against neuronal disorders.

세계 최초의 자폐증 치료제 개발을 위한 후보물질(NV01-A02) FDA 희귀의약품 지정에 성공한 뉴로벤티(NeuroVenti)는 최근 특허청으로부터 자폐스펙트럼장애를 비롯한 정서장애 치료에 관한 신규 물질특허 등록을 통보 받아 현재 자폐스펙트럼장애 치료제의 국내 임상 2상 준비중으로, 중추신경계 장애에 대한 치료제 후보 발굴, 비임상 연구 컨설팅, 후보 물질의 비임상 효능 평가 및 안전성 평가를 위한 연구 서비스 등 비임상 CDRO도 제공하고 있습니다.

Read More

Pipeline

Introduce the pipeline of NeuroVenti

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-A02

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-A03

Development for Autism spectrum disorder

Autism Spectrum Disorder - NV01-O62

R&D Services

Introducing NeuroVenti's core research capabilities

- A variety of neurological disease models, in vivo and in vitro efficacy assessment system, and a system for mechanistic studies
- Establish the best research plan for your needs through the preclinical research consulting
- Select models, preliminary experiments, and establish evaluation methods through consultation after applying collaboration and research services
- Provide customer-oriented and optimized evaluation services

View More

News

2024 - Happy New Year of Blue Dragon

The Year of the Blue Dragon has dawned.Happy New Year!We, Neuventi, will support you in a year where you fly high with t…
2024 - Happy New Year of Blue Dragon

Good bye 2023

2023 is coming to an end.There have been many things going on both internally and externally, but we've been working har…
Good bye 2023

New Drug Target SICC/NeuroVenti Joint Worksho…

On Thursday, December 15, 2023, NeuroVenti and Gyeongsang National University jointly held a workshop under the theme of…
New Drug Target SICC/NeuroVenti Joint Worksho…

[YTN] Studies show that it can cause cannabis…

The study, published in Nature Genetics, a sister journal of Nature, is a large-scale study that looked at how human gen…
[YTN] Studies show that it can cause cannabis…

[ASD Related Information] Environmental Expos…

[ASD Related Information] Environmental Exposure and ASD Risk※ Intro- Even at this moment, researchers are actively inve…
[ASD Related Information] Environmental Expos…

[ASD Related Information] Genetic Disorder an…

[ASD Related Information] Genetic Disorder and Autism Spectrum Disorder (ASD)※ Genetic testNowadays, even minute changes…
[ASD Related Information] Genetic Disorder an…

[ASD Related Information] Genetic Disorder an…

[ASD Related Information] Genetic Disorder and Autism Spectrum Disorder (ASD)※ 22q13.3 Microdefective Syndrome (Phelan-M…
[ASD Related Information] Genetic Disorder an…

[ASD Related Information] Genetic Disorder an…

[ASD Related Information] Genetic Disorder and Autism Spectrum Disorder (ASD)※ 16p11.2 microdeletions syndromeIt is a di…
[ASD Related Information] Genetic Disorder an…

Business area

Realizing Brain Wellness Society through Treatment of Neurodevelopmental Disorders
and Intractable Neurological Diseases, and Optimal Utilization of Brain Function

Drug
Development
CNS disorders’
therapeutic
candidates
research service
Platform
technology